Immunotherapy of hematological malignancies using dendritic cells

Bulletin du Cancer

Volumn 95, Issue 3, 2008, Pages 320-326

  Van De Velde, Ann L R ^a   Berneman, Zwi N ^a,b   Van Tendeloo, Viggo F I ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Dendritic cell; Hematological malignancies; Immunotherapy; T cell mediated therapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYTARABINE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERLEUKIN 2; PROTEIN PR1; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DENDRITIC CELL; DRUG MECHANISM; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE SYSTEM; IMMUNOGLOBULIN DEFICIENCY; IMMUNOTHERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; LEUKEMIA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MULTIPLE MYELOMA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 42149156663     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0602     Document Type: Review

References (66)

1. Zhang WG, Liu SH, Yang Y, et al. A phase-I clinical trial of active immunotherapy for acute leukaemia using inactivated autologous leukaemia cells mixed with IL-2, GM-CSF, and IL-6. Leukemia Res 2005; 29: 3-9.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
3. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52-8.
4. Fujii S, Shimizu K, Kinoshita M, et al. Analysis of a chronic myelogenous leukaemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res 1999; 90: 1117-29.
5. Lesterhuis WJ, Punt CJA, et al. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann Oncol 2004; 15(S4): iv145-iv151.
6. Rey J, Olive D, Sebahoun G, et al. New insights into cytotoxic effector cells. Bull Cancer 2005; 92: 935-43.
7. Montagna D, Maccario R, Bonetti F, et al. Emergence of antitumor cytolytic T cells is associated with maintenance of hematological remission in children with acute myeloid leukemia. Blood 2006; 108: 3843-50.
8. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007; 121: 1-14.
9. Abastado JP. Cellular immunotherapy: complexity of immune system and industrial development. Bull Cancer 2003; 90: 789-94.
10. Vuillier F, Dighiero G. Cell therapy by dendritic cells in chronic lymphoid leukemia: state of the art. Bull Cancer 2003; 90: 744-50.
11. Figdor C, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10: 475-80.
12. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5: 296-306.
13. Morse MA. Current status of dendritic cell vaccines. 2002. www.medscape.com/viewarticle/440750_15.
14. Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98: 49-56.
15. Ponsaerts P, Van Tendeloo VFI, Berneman ZN. Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol 2003: 1-7.
16. Blander JM, Medhzitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440: 808-12.
17. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711.
18. Smits EL, Ponsaerts P, Van Tendeloo VF, et al. Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells. Leukemia 2007; 21: 1691-9.
19. Gosse J. Adema, I Jolanda M de Vries, Cornelis JA Punt, Carl G Figdor. Migration of dendritic cell based cancer vaccines: in vivo Veritas? Curr Opin Immunol 2005; 17: 170-4.
20. Kyte JA, Mu L, Aamdal S, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006; 13: 905-18.
21. Palucka AK, Banchereau J. Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma. J Immunother 2005; 28: 158-68.
22. Zhong RK, Loken M, Ball ED, et al. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. Cytotherapy 2006; 8: 3-12.
23. Dannull J, Su Z, Yancey D, et al. Enhancement of vaccine-mediated anti-tumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623-33.
24. DeVries IJ, Bernsen MR, Lesterhuis WJ, et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vacination correlates with clinical outcome. J Clin Oncol 2005; 23: 5779-87.
25. Borg C, Taieb J, Zitvogel L, et al. NK-cell based immunotherapy: new prospects and involvement of dendritic cells. Bull Cancer 2003; 90: 699-705.
26. Chaput N, Taieb J, Zitvogel L. Innate defence against tumor cells: the killer cell IKDC. Bull Cancer 2006; 93: 449-51.
27. Bendandi M, Gocke CD, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171-7.
28. Ruffini PA, Neelapu SS, Biragyn A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologia (Budap) 2002; 87: 989-1001.
29. Lim SH, Bailey-Wood R. Idiotypic-protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999; 83: 215-22.
30. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood 1999; 93: 2411-9.
31. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000; 108: 805-16.
32. Kwak LW. Translational development of active immunotherapy for hematological malignancies. Semin Oncol 2003; 30: 17-22.
33. Yi Q, Desikan R, Barlogie B, et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 2002; 117: 297-305.
34. Yi Q. Dendritic cell-based immunotherapy in multiple myeloma. Leuk Lympoma 2003; 44: 2031-8.
35. Rasmussen T, Hansson L, Mellstedt H, et al. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 200; 101: 4607-10.
36. Guardino AE, Rajapaksa R, Levy R, et al. Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma. Cytotherapy 2006; 8: 277-89.
37. Crainie M, Belch AR, Mant MJ, et al. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood 1999; 93: 1684-96.
38. Maxwell CA, Rasmussen E, Zhan F, et al. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 2004; 104: 1151-8.
39. Maier T, Tun-Kyi A, Tassis A, et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumour-lysate-pulsed dendritic cells. Blood 2003; 102: 2338-44.
40. Schmitt A, Hus I, Schmitt M. Dendritic cell vaccines for leukemia patients. Expert Rev Anticancer Ther 2007; 7: 275-83.
41. Greiner J, Dohner H, Schmidtt M. Cancer vaccines for patients with acute myeloid leukaemia-definition of leukaemia-associated antigens an current clinical protocols targeting these antigens. Haematologica 2006; 91: 1653-61.
42. Guinn BA, Mohamedali A, Mills K, et al. Immunotherapy of myeloid leukaemia. Cancer Immunol Immunother 2007; 56: 943-57.
43. Greiner J, Li L, Schmitt M, et al. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukaemia. Blood 2005; 106: 938-45.
44. Scheibenbogen C, Letsch A, Keilholz U, et al. CDS T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132-7.
45. Oka Y, Tsuboi A, Sugiyama H, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885-90.
46. Mailänder V, Scheibenbogen C, Keilholz U, et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18: 165-6.
47. Van Driessche A, Gao L, Van Tendeloo VF, et al. Antigen-specific cellular immunotherapy of leukemia. Leukemia 2005; 19: 1863-71.
48. Qazilbash MH, Wieder E, Couriel D, et al. Vaccination with the PR1 leukaemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood 2004; 104: 259.
49. Ossenkoppele GJ, Stam AG, van de Loosdrecht, et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 2003; 17: 1424-6.
50. Litzow MR, Dietz AB, Hoering A, et al. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy 2006; 8: 290-8.
51. Houtenbos I, Westers TM, van de Loosdrecht AA, et al. Feasibility of clinical dendritic cell vaccination in acute myeloid leukaemia. Immunobiology 2006; 211: 677-85.
52. Li L, Giannopoulos K, Greiner J, et al. Immunotherapy for patients with acute myeloid leukaemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol 2006; 28: 855-61.
53. Roddie H, Klammer M, Sproul A, et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol 2006; 133: 152-7.
54. Mohty M, Gaugler B, Chabannon C, Olive D, et al. Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches. Bull Cancer 2003; 90: 751-7.
55. Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia. Biomed Pharmacother 2001; 61: 306-14.
56. Bocchia M, Gentili S, Tabilio A, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 657-62.
57. Cathcart K, Pinilla-Ibarz J, Papadopoulos EB, et al. A multivalent BCR-ABL fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037-42.
58. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517-26.
59. Hus I, Rolinski J, Schmitt M, et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 1621-7.
60. Reichardt VL, Milazzo C, Brossart P, et al. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. J Haematol 2003; 88: 1139-49.
61. Chang DH, Osman K, Dhodapkar MV, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of αglactosyl-ceramide loaded mature dendritic cells in cancer patients. JEM 2005; 201: 1503-17.
62. Bendandi M, Rodriguez-Calvillo M, Orfao A, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma 2006; 47: 29-37.
63. Westermann J, Kopp J, Pezzutto A, et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br J Haematol 2001; 137: 297-306.
64. Rezvani K, Yong ASM, Barrett AJ, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236-42.
65. Schmitt M, Schmitt A, Greiner J, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunological and clinical responses. Blood 2008; 111: 1357-65.
66. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117: 1195-203.